Literature DB >> 11502217

Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells.

C Oetke1, S Hinderlich, R Brossmer, W Reutter, M Pawlita, O T Keppler.   

Abstract

Sialic acids are the most abundant terminal carbohydrate moiety on cell surface glycoconjugates in eukaryotic cells and are of functional importance for many biological ligand-receptor interactions. It is a widely accepted view that sialic acids cannot be efficiently taken up from the extracellular space by eukaryotic cells. To test this assumption, we cultivated two recently identified human hematopoetic cell lines which are hyposialylated due to a deficiency in de novo sialic acid biosynthesis in the presence of N-acetylneuraminic acid (NeuAc), the most frequently found sialic acid. Surprisingly, NeuAc medium supplementation rapidly and potently compensated for the endogenous hyposialylation in a concentration-dependent manner, resulting in the presentation of cell surface sialoglycans involved in cell adhesion, virus infection and signal transduction. We provide several lines of experimental evidence that all suggest that NeuAc was neither extracellularly incorporated nor degraded to a less complex sugar before uptake. Importantly, NeuAc induced a marked increase in intracellular CMP-NeuAc levels in both human cell lines and in primary cells regardless of the prior sialylation status of the cells. Studies employing 9-[3H]NeuAc revealed an uptake consistent with the observed incorporation of unlabeled NeuAc. We propose the existence of an efficient uptake mechanism for NeuAc in eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502217     DOI: 10.1046/j.1432-1327.2001.02379.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  35 in total

1.  Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.

Authors:  Haitham A Badr; Dina M M AlSadek; Mohit P Mathew; Chen-Zhong Li; Leyla B Djansugurova; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2015-08-10       Impact factor: 12.479

2.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

3.  Glycoproteomics enabled by tagging sialic acid- or galactose-terminated glycans.

Authors:  T N C Ramya; Eranthie Weerapana; Benjamin F Cravatt; James C Paulson
Journal:  Glycobiology       Date:  2012-10-15       Impact factor: 4.313

Review 4.  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.

Authors:  Haitham A Badr; Dina M M AlSadek; Motawa E El-Houseini; Christopher T Saeui; Mohit P Mathew; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

5.  High-efficiency labeling of sialylated glycoproteins on living cells.

Authors:  Ying Zeng; T N C Ramya; Anouk Dirksen; Philip E Dawson; James C Paulson
Journal:  Nat Methods       Date:  2009-02-22       Impact factor: 28.547

6.  Fluorination of mammalian cell surfaces via the sialic acid biosynthetic pathway.

Authors:  Laila Dafik; Marc d'Alarcao; Krishna Kumar
Journal:  Bioorg Med Chem Lett       Date:  2008-09-06       Impact factor: 2.823

7.  Bioorthogonal metabolic glycoengineering of human larynx carcinoma (HEp-2) cells targeting sialic acid.

Authors:  Arne Homann; Riaz-Ul Qamar; Sevnur Serim; Petra Dersch; Jürgen Seibel
Journal:  Beilstein J Org Chem       Date:  2010-03-08       Impact factor: 2.883

8.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

9.  Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.

Authors:  Mariano R Gabri; Laura L Otero; Daniel E Gomez; Daniel F Alonso
Journal:  J Exp Clin Cancer Res       Date:  2009-12-01

10.  Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).

Authors:  Chris Jay; Gregory Nemunaitis; John Nemunaitis; Neil Senzer; Stephan Hinderlich; Daniel Darvish; Julie Ogden; John Eager; Alex Tong; Phillip B Maples
Journal:  Gene Regul Syst Bio       Date:  2008-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.